.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Deloitte
Daiichi Sankyo
Argus Health
Cerilliant
Mallinckrodt
Citi
Cantor Fitzgerald
Medtronic
Merck

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,173,859

« Back to Dashboard

Which drugs does patent 9,173,859 protect, and when does it expire?


Patent 9,173,859 protects JENTADUETO XR, GLYXAMBI, JENTADUETO, and TRADJENTA, and is included in four NDAs. There have been zero Paragraph IV challenges on Tradjenta and Jentadueto

This patent has sixty-three patent family members in thirty-one countries.

Summary for Patent: 9,173,859

Title:Uses of DPP IV inhibitors
Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Inventor(s): Dugi; Klaus (Dresden, DE), Himmelsbach; Frank (Mittelbiberach, DE), Mark; Michael (Biberach an der Riss, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:14/161,007
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimJENTADUETO XRlinagliptin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimJENTADUETO XRlinagliptin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-001Jan 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-002Jan 30, 2015RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-003Jan 30, 2012RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-001Jan 30, 2012RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-002Jan 30, 2012RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
Boehringer IngelheimTRADJENTAlinagliptinTABLET;ORAL201280-001May 2, 2011RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
Boehringer IngelheimTRADJENTAlinagliptinTABLET;ORAL201280-001May 2, 2011RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,173,859

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06009203May 4, 2006

Non-Orange Book Patents for Patent: 9,173,859

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,232,281Uses of DPP-IV inhibitors► Subscribe
8,673,927Uses of DPP-IV inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,173,859

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101460173► Subscribe
China102125560► Subscribe
China102846619► Subscribe
Israel195031► Subscribe
Japan2009535381► Subscribe
CroatiaP20140645► Subscribe
European Patent Office2397142► Subscribe
European Patent Office2407168► Subscribe
Spain2474866► Subscribe
Hong Kong1204548► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
Boehringer Ingelheim
Chubb
US Department of Justice
McKesson
Novartis
UBS
Cerilliant
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot